AstraZeneca is a catalyst-rich global biopharma compounder using oncology leadership, precision medicine, and superior R&D productivity to pursue Ambition 2030 while navigating pricing and patent-cliff risks.
Overview
AstraZeneca has transformed into a science-led global biopharma compounder focused on Oncology, CVRM, Respiratory & Immunology, and Rare Disease. With 16 blockbuster medicines, 186 pipeline projects, and Ambition 2030 targeting $80 billion in revenue, the company offers rare large-cap pharmaceutical growth. Its diversified global footprint—led by the U.S., Europe, China, and emerging markets—reduces regional dependence, while precision medicines, biologics, and ADCs provide clinical differentiation, pricing resilience, and durable competitive advantages.